Axaron Bioscience AG
today announced the launch of
iGentifier, a novel
transcription profiling technology for the agricultural, food,
feed, and pharmaceutical industry. This expert technology
enables customers to identify genes and biochemical pathways -
central to, for example, crop and fungal productivity,
pathogenesis and the response to stress factors.
Compared to conventional technologies, iGentifier
offers key advantages in terms of robustness, sensitivity and
reliability. Combining the advantages of fragment display with
tag sequencing methods, iGentifier can detect even the
most subtle changes in gene expression. This technology ensures
time- and cost-effective transcription analysis that
exceeds the limits of microarrays.
Customers benefit from high quality of data regardless of
species, sample numbers, or tissue of interest, thereby
achieving their goals earlier and seeing a faster return on
investment. Axaron’s novel iGentifier technology can be
customized to fit seamlessly into customers’ existing genomic
platform or as a complete service solution. BASF AG is Axaron’s
first customer to use the iGentifier service as part of
its crop protection program.
Axaron’s CEO, Dr Alfred Bach comments, "iGentifier is
the latest addition to Axaron’s cutting-edge functional genomics
and proteomics platform. Based on more than six years experience
with customers, we developed iGentifier to combine the
advantages of all currently available open transcription
profiling technologies. We are convinced that this novel
technology will set new standards in transcription profiling in
the Life Sciences industry."
Axaron Bioscience is a biotechnology company, which is
focused on becoming a leader in developing innovative CNS
medicines. The company is in a strong position to achieve this
goal based on its unique integrated functional genomics and
proteomics technology platform and its world-leading network of
collaborating experts in the CNS field. Axaron has already
generated an exciting pipeline of drug candidates for the
treatment of stroke due to enter Phase II clinical trials later
in 2003. Axaron is located in Heidelberg, Germany one of the
world’s leading clusters for CNS research. Axaron was founded in
1997 as BASF-LYNX, a joint venture between the German BASF AG
and the US biotechnology company Lynx.